1083326-46-8

Basic information

• Product Name: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetamide
• Synonyms: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetamide;4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-acetamide;2-[4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]acetaMide;1H-Pyrazole-1-acetaMide, 4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetamide;(1-(2-AMINO-2-OXOETHYL)-1H-PYRAZOL-4-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 1083326-46-8
• Molecular Formula: C₁₁H₁₈BN₃O₃
• Molecular Weight: 251
• Mol File: 1083326-46-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 440.8±25.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 15?+-.0.40(Predicted)
• CAS DataBase Reference: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetamide(1083326-46-8)
• EPA Substance Registry System: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetamide(1083326-46-8)

Safety Data

• Hazardous Substances Data: 1083326-46-8(Hazardous Substances Data)

Usage

Uses

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-acetamide, can be used in the preparation of pharmaceutical and biologically active compounds, including inhibitors and therapeutic agents.

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 683-57-8 bromo-acetic acid amide 

Downstream Products

• 1220690-49-2 2-(4-(5-(3-(cyclopentyloxy)-4-methoxybenzylamino)pyridin-3-yl)-1H-pyrazol-1-yl)acetamide 

Relevant articles and documents

DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.

P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.